Drug intelligence / Profile preview

pembrolizumab + irinotecan

Development stage: Phase 2
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Pembrolizumab + irinotecan is an investigational combination regimen consisting of the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) and the topoisomerase I inhibitor chemotherapy agent irinotecan. This combination is being evaluated in clinical trials, including a Phase 1b/2 trial sponsored by Yonsei University for the treatment of metastatic or recurrent malignant melanoma, and a Phase 2 trial for high-grade neuroendocrine cancer. The therapeutic rationale is to combine the cytotoxic, DNA-damaging effects of irinotecan with the immune checkpoint blockade of pembrolizumab to enhance anti-tumor efficacy and potentially overcome resistance in advanced solid tumors.

Other names: irinotecan + pembrolizumabpembrolizumab and irinotecanpembrolizumab/irinotecan

Targets

CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on pembrolizumab + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + irinotecan.